Trials / Unknown
UnknownNCT05431569
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.
Detailed description
36 to 64 patients with advanced lung cancer who failed pD-1 /L1 inhibitor treatment will be inrolled. Cohort 1:20 to 33 patients with non-small cell lung cancer (NSCLC) Cohort 2:16 to 31 patients with small cell lung cancer (SCLC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 6MW3211 | 6MW3211 injection ,30mg/kg,iv drip，Q2W |
Timeline
- Start date
- 2022-07-10
- Primary completion
- 2022-12-10
- Completion
- 2023-09-10
- First posted
- 2022-06-24
- Last updated
- 2022-06-24
Source: ClinicalTrials.gov record NCT05431569. Inclusion in this directory is not an endorsement.